Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Doximity filings document financial results, material events, governance actions, and capital-structure details for the operator of a digital platform for U.S. medical professionals. Recent Form 8-K disclosures cover quarterly results and related exhibits, finance and legal leadership changes, Regulation FD updates, and annual-meeting voting outcomes.
The company's regulatory record also includes shareholder voting matters tied to its Class A and Class B common stock structure, director elections, auditor ratification, material agreements, and other security-holder matters. These filings describe how Doximity reports operating performance, governance changes, voting mechanics, and formal public-company events.
Doximity director Kira Scherer Wampler reported a routine set of equity transactions involving stock options and share sales. On February 2, 2026, she exercised a stock option for 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, which were convertible into Class A shares.
Those 2,000 Class B shares were converted into 2,000 Class A Common Stock and then sold the same day at a price of $37.33 per share under a pre-established Rule 10b5-1 trading plan. After these transactions, Wampler directly held 19,839 shares of Class A Common Stock and 458,700 derivative securities in the form of options tied to Class B Common Stock.
Doximity insider Kira Wampler has filed a notice to sell company stock. The filing reports a planned sale of 2,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $74,660 and 137,373,858 shares outstanding.
The 2,000 shares were acquired on February 2, 2026 via a stock option exercise paid in cash on the same date. Over the past three months, Wampler has already sold three separate 2,000-share blocks of Doximity common stock, with gross proceeds of $101,420, $132,880, and $89,300.
Doximity, Inc. director Form 4 shows option exercise, share conversion, and a small sale under a preset plan. On 01/02/2026, the reporting person exercised a stock option for 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, receiving an equivalent 2,000 Class B shares that are convertible into Class A shares.
That same day, 2,000 shares of Class B Common Stock converted into 2,000 shares of Class A Common Stock, and 2,000 Class A shares were sold at a price of $44.65 per share. After these transactions, the director beneficially owned 19,839 shares of Class A Common Stock directly and held 460,700 derivative securities in the form of stock options. The filing notes that the sale was made automatically under a Rule 10b5-1 trading plan adopted on November 12, 2024, indicating the trades were pre-arranged.
A shareholder of Doximity has filed a notice under Rule 144 to sell 2,000 shares of Doximity common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $89,300. These shares were acquired on the same date via a stock option exercise paid in cash.
Over the prior three months, the same seller disposed of an additional 4,000 common shares in two transactions, generating gross proceeds of $101,420 and $132,880. The filing notes that Doximity had 137,373,858 common shares outstanding at the time referenced, providing context for the size of the planned sale.
Doximity, Inc. reported that it has entered into an Agreement of Settlement to resolve a securities litigation case pending in the U.S. District Court for the Northern District of California. The proposed settlement calls for an aggregate payment of $31 million, which will be fully funded by insurance proceeds rather than by the company directly. If approved by the court and all conditions are met, all claims against Doximity and the named directors and officers will be dismissed without any admission of liability, fault or wrongdoing. The settlement is still subject to stockholder notice, court approval, and other customary conditions, and the company notes that appeals, opt-outs by individual plaintiffs, or issues with insurance carriers could affect the final outcome.
Doximity, Inc. director Form 4 shows an option exercise, share conversion and a small stock sale. On 12/01/2025, the reporting director exercised a stock option to acquire 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, which then converted into 2,000 shares of Class A Common Stock. The director sold 2,000 Class A shares at a price of $50.71 per share under a pre-set Rule 10b5-1 trading plan adopted on November 12, 2024. After these transactions, the director directly owned 19,839 shares of Class A Common Stock and held derivative securities representing 462,700 shares of Class B Common Stock, which are convertible into Class A shares under specified conditions.
Doximity insider files notice to sell common stock under Rule 144. The filing reports a planned sale of 2,000 shares of Doximity common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $101,420.00. These 2,000 shares were acquired on 12/01/2025 via a stock option exercise paid in cash on the same date. Common shares outstanding are listed as 137,373,858.
The filer also discloses prior sales over the past three months: 2,000 common shares on 11/03/2025 for gross proceeds of $132,880.00, 2,000 shares on 10/01/2025 for $140,020.00, and 2,000 shares on 09/02/2025 for $133,140.00. The signer represents that they are not aware of undisclosed material adverse information about Doximity.
Doximity, Inc. (DOCS) reported an insider transaction by a director on 11/21/2025. The director converted 10,000 shares of Class B Common Stock into Class A Common Stock and then sold 10,000 shares of Class A Common Stock at $50 per share.
The filing notes that the sale occurred automatically under a Rule 10b5-1 trading plan adopted on February 13, 2025. After these transactions, the director directly owned 3,221 shares of Class A Common Stock and held 333,500 derivative securities, including stock options originally granted on September 2, 2020.
A shareholder of DOCS has filed a Form 144 notice to sell up to 10,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE. The planned sale has an aggregate market value of $500,000, and the filing notes that 137,373,858 shares of common stock are outstanding.
The 10,000 shares to be sold were acquired on 11/21/2025 via a stock option exercise from the issuer, paid in cash on the same date. Over the prior three months, the same seller, Timothy Cabral, reported sales of 20,000 shares of common stock on 09/24/2025 for gross proceeds of $1,500,000 and 6,360 shares on 09/02/2025 for gross proceeds of $421,655.28.
Doximity, Inc. (DOCS) reported a routine insider equity transaction by its Chief Financial Officer on a Form 4. On 11/15/2025, 5,121 shares of Class A common stock were withheld at a price of $49.62 per share to cover tax withholding obligations tied to the vesting of previously granted restricted stock units. After this tax-related withholding, the officer beneficially owns 364,672 shares of Class A common stock directly. The filing specifies that the share withholding followed an issuer election made in advance and does not represent a discretionary trade or open-market sale by the reporting person.